Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. Their mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the “stress pathway”). They are committed to transforming the quality of life for patients who have been underserved by scientific innovation. Founded by Alexis Howerton in 2014, Spruce Biosciences is backed by investors that include RiverVest, Novo Holding and is headquartered in San Francisco.